http://purl.org/np/RAAVjkZUGQ... RAAVjkZUGQ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-14T06:58:30.606Z

http://purl.org/np/RAAVjkZUGQ... RAAVjkZUGQ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old information related to usage of rizatriptan benzoate in pediatric patients 6 to 17 years old is approved for merck co inc s rizatriptan benzoate tablets however due to merck co inc s marketing exclusivity rights this drug product is not labeled with that pediatric patient 6 to 17 years old usage information limitations of use rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established if a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets is administered to treat any subsequent attacks rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine see contraindications 4 rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks safety and effectiveness of rizatriptan benzoate tablets have not been established for cluster headache rizatriptan benzoate tablets are a serotonin 5 ht 1b 1d receptor agonist triptan indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age 1 limitations of use use only after clear diagnosis of migraine has been established 1 not indicated for the prophylactic therapy of migraine 1 not indicated for the treatment of cluster headache 1

Leoni Bücken

2021-06-14T06:58:30.606Z

http://purl.org/np/RAAVjkZUGQ... RAAVjkZUGQ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_6364 DOID_6364

Leoni Bücken

2021-06-14T06:58:30.606Z

http://purl.org/np/RAAVjkZUGQ... RAAVjkZUGQ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-14T06:58:30.606Z

http://purl.org/np/RAAVjkZUGQ... RAAVjkZUGQ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00953 drugbank:DB00953

Leoni Bücken

2021-06-14T06:58:30.606Z

http://purl.org/np/RAAVjkZUGQ... RAAVjkZUGQ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-14T06:58:30.606Z

http://purl.org/np/RAAVjkZUGQ... RAAVjkZUGQ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-14T06:58:30.606Z

http://purl.org/np/RAAVjkZUGQ... RAAVjkZUGQ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-06-14T06:58:30.606Z